Searching for your content...
from 8 AM - 10 PM ET
Amblyotech, a US-based digital therapeutics company, announced that it has completed the sale of all of its outstanding shares to Novartis pursuant...
Join PR Newswire for Journalists to access all of the free services designated to make your job easier.
In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.